TNP-470 combined with nicardipine suppresses in vivo growth of PC-3, a human prostate cancer cell line.
We examined effects of TNP-470 with or without nicardipine on in vivo or in vitro growth of a hormone-independent human prostate carcinoma cell line, PC-3. TNP-470 (30 mg/kg, daily) or nicardipine (25 microg/kg, daily) alone had little effects on in vivo growth of PC-3 cells in nude mice, whereas simultaneous administration of both agents significantly inhibited the growth of the xenografts. In vitro proliferation of PC-3 was not affected by TNP-470 and/or nicardipine. Combination of TNP-470 and nicardipine seems beneficial in the treatment of hormone-refractory prostate cancer.
Arisawa
Chizuru
C
Department of Urology and Reproductive Medicine, Graduate School, Tokyo Medical and Dental University 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Kageyama
Yukio
Y
Kawakami
Satoru
S
Kihara
Kazunori
K
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D003114:Colony-Forming Units Assay; D003510:Cyclohexanes; D004195:Disease Models, Animal; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy; D009529:Nicardipine / Q000008:administration & dosage; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D011471:Prostatic Neoplasms / Q000473:pathology*; D012717:Sesquiterpenes / Q000008:administration & dosage; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
D003510:Cyclohexanes; D012717:Sesquiterpenes; D009529:Nicardipine; D000077609:O-(Chloroacetylcarbamoyl)fumagillol